Research Library
An evidence library, not a catalogue.
Each entry describes what researchers are studying, in neutral language, alongside a regulatory status badge and an evidence level. Nothing here is offered for sale, and no dosing or self-administration guidance is provided.
13 of 13 entries
Tissue & gastrointestinal research
BPC-157 5 mg
A synthetic pentadecapeptide sequence derived from a gastric protein. Researchers are studying its effects on soft-tissue and gastrointestinal repair processes in laboratory and animal models.
Research-onlyEvidence: PreclinicalResearch summaryTissue & cytoskeletal research
TB-500 5 mg
A synthetic fragment related to thymosin beta-4. Studied in preclinical models for its role in cell migration and tissue remodelling processes.
Research-onlyEvidence: PreclinicalResearch summarySkin & matrix research
GHK-Cu 50 mg
A copper-binding tripeptide studied for its role in extracellular matrix signalling. Widely used topically in cosmetic science; injectable use is not an approved application.
Status varies — confirm locallyEvidence: EmergingResearch summaryMetabolic research — investigational
Retatrutide 5 mg
An investigational triple receptor agonist under clinical development. It is NOT approved for public use anywhere and should be regarded strictly as a research and clinical-trial compound.
InvestigationalEvidence: EmergingResearch summaryNeuroscience research
Semax 5 mg
A synthetic ACTH-fragment analogue studied in neuroscience research. Registered as a medicine in a small number of countries only; not registered in South Africa.
Status varies — confirm locallyEvidence: InsufficientResearch summaryNeuroscience research
Selank 5 mg
A synthetic analogue of the immunomodulatory peptide tuftsin, studied in anxiety-related and neuroimmune research contexts.
Status varies — confirm locallyEvidence: InsufficientResearch summaryEndocrine research
Ipamorelin / CJC-1295 10 mg
A research combination of a growth-hormone secretagogue and a GHRH analogue. Studied in endocrine research; not an approved therapeutic combination.
Research-onlyEvidence: PreclinicalResearch summaryEndocrine — approved in some markets
Tesamorelin 5 mg
A GHRH analogue approved in certain markets for a specific, narrowly defined clinical indication under prescription and specialist oversight.
Approved medicineEvidence: EstablishedResearch summarySkin & matrix research blend
KLOW 80 mg
A research blend combining several peptide sequences studied in skin and tissue-matrix contexts. Blends are not registered medicines and have no established clinical evidence base.
Research-onlyEvidence: InsufficientResearch summaryMetabolic — approved in some markets
Tirzepatide 5 mg
A dual GIP/GLP-1 receptor agonist approved in several markets as a prescription medicine. Only registered, prescribed product from licensed channels should ever be considered.
Approved medicineEvidence: EstablishedResearch summaryCellular metabolism research
NAD+ 100 mg
A coenzyme central to cellular energy metabolism. Widely studied in ageing biology; injectable and infusion presentations are not established approved therapies.
Status varies — confirm locallyEvidence: EmergingResearch summaryMetabolic research — early stage
SLU-PP-332 5 mg
An early-stage experimental ERR agonist compound studied in animal models of exercise-related metabolism. Preclinical only.
Research-onlyEvidence: PreclinicalResearch summaryImmunology research
KPV 5 mg
A tripeptide fragment of alpha-MSH studied in preclinical inflammation and mucosal immunity research.
Research-onlyEvidence: PreclinicalResearch summary
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.